spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Palatin Technologies 

 HSMN NewsFeed - 22 Feb 2022
TC Biopharm Announces Appointment of New Board Members
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Jun 2021
Palatin Announces New Additions to Its Senior Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jun 2019
Palatin Technologies Granted FDA Orphan Drug Designation -- PL-8177 for the Treatment of Non-Infectious Uveitis
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 10 Apr 2017
Non-Opioid Drug Development Firm, CerSci Therapeutics, Announces Appointment of Pharma Leaders Pat Confalone and Perry Molinoff to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Feb 2017
Palatin Technologies Announces Closing of License Agreement with AMAG Pharmaceuticals for North American Rights to Rekynda(TM)
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 4 Feb 2016
Lion Biotechnologies Names Steven A. Fischkoff Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Dec 2015
Derma Sciences Announces Leadership and CEO Transition
Devices Regenerative Medicine Wound Care Personnel
 HSMN NewsFeed - 28 Apr 2014
Actinium Announces Key Additions to Senior Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Sep 2013
Actinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Dec 2010
Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Nov 2010
Palatin Technologies Appoints Jeffrey D. Edelson, M.D., Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jan 2010
Adolor Corporation Announces Management Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jan 2008
Palatin Technologies Announces Litigation Settlement With Competitive Technologies
Biopharmaceuticals Licensing Litigation
 HSMN NewsFeed - 26 Sep 2007
Palatin Technologies Announces Reduction of Workforce
Biopharmaceuticals
 HSMN NewsFeed - 30 Aug 2007
King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
Biopharmaceuticals
 HSMN NewsFeed - 21 May 2007
Intercept Pharmaceuticals Expands Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Dec 2006
Palatin Technologies and King Pharmaceuticals Complete Enrollment in Pre-Menopausal Cohort of a Phase 2 Clinical Trial Evaluating Bremelanotide in Pre- and Post-Menopausal Female Sexual Dysfunction Patients
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2006
Palatin Technologies and King Pharmaceuticals Report Results For Two Phase 2B Clinical Trials Evaluating Bremelanotide in Male Erectile Dysfunction Patients
Biopharmaceuticals
 HSMN NewsFeed - 28 Jul 2006
Steven Fischkoff, M.D. Joins Palatin Technologies as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 May 2006
Palatin Technologies and King Pharmaceuticals Complete Enrollment in Two Phase IIb Clinical Trials Evaluating Bremelanotide in Patients with Erectile Dysfunction
Biopharmaceuticals
 HSMN NewsFeed - 7 Feb 2006
Palatin Technologies and King Pharmaceuticals Initiate Phase IIb Clinical Trial Evaluating PT-141 in Patients Suffering From Female Sexual Arousal Disorder
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 20

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 20 additional stories matching:
Palatin Technologies
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.